Continued Growth During 2023 – Milestones and Achievements
What a year 2023 has been. A year of remarkable growth and achievements, award-winning, and new standards in gmp manufacturing facilities.
What a year 2023 has been. A year of remarkable growth and achievements, award-winning, and new standards in gmp manufacturing facilities.
Upperton Pharma Solutions, a leading contract development and manufacturing organisation (CDMO) specialising in the development and manufacture of innovative drug formulations, has been announced as a winner of the King’s Award for Enterprise, International Trade. The King’s Award for Enterprise is a highly prestigious award for UK businesses who have demonstrated outstanding innovation in their industry. … Read more
Leading UK contract development and manufacturing organisation (CDMO), Upperton Pharma Solutions has completed the build of its new development and GMP manufacturing headquarters in Nottingham, UK. Situated less than two miles from Upperton’s current HQ, the facility ‘Trent Gateway’ houses ten new GMP manufacturing suites, quality control laboratories and formulation development with pilot plant capabilities. … Read more
An introduction to nasal delivery The delivery of APIs via nasal inhalation is of growing interest to companies looking to exploit the benefits of this delivery route. Delivery targets are typically broken down into three categories Local delivery to the nasal membranes (e.g. for vaccines, antivirals, prophylactics) Systemic delivery by absorption into the bloodstream (e.g. … Read more
20th April 2023 : Press Release Nottingham, UK, 20th April: Leading UK contract development and manufacturing organisation (CDMO) Upperton Pharma Solutions (Upperton) has expanded its oral dosage form capabilities at its newly built headquarters in Nottingham, UK. Part of Upperton’s £15m investment program announced in January this year, the state-of-the-art facility has benefited from a … Read more
Introduction to Nasal Delivery The delivery of APIs via nasal inhalation is of growing interest to companies looking to exploit the benefits of this delivery route.Delivery targets are typically broken down into three categories Local delivery to the nasal membranes (e.g. for vaccines, antivirals, prophylactics) Systemic delivery by absorption into the bloodstream (e.g. for fast … Read more
January 31st 2023 : Newsletter The New Year is always a time for looking ahead and 2023 will no doubt turn out to be a pivotal year in the Upperton Pharma Solutions growth story. In this Newsletter we will be previewing some of the exciting new plans that we have in store for ourselves and … Read more
18th January 2023 Upperton Pharma Solutions, a leading UK contract development and manufacturing organisation (CDMO), is delighted to announce that it has begun construction work for its new Development and GMP Manufacturing headquarters in Nottingham, UK. Working in close collaboration with its principal Design and Build contractor, T-SQUARED the team officially broke ground on the … Read more
29th November 2022 – Press Release & Newsletter Upperton Pharma Solutions Appoints T-SQUARED for Design and Build of New Development and Manufacturing Facility Upperton Pharma Solutions, a leading UK contract development and manufacturing organisation (CDMO), is delighted to announce that it has appointed T-SQUARED, UK based company, as the principal Design and Build contractor for … Read more
November 16th 2022 : Newsletter Upperton has made a significant investment in ASAPprime® software and hardware to enable the company to offer its clients state of the art stability testing. This exciting new platform can be used to generate robust, accelerated chemical stability data and is now being applied at all stages of the product … Read more